by Alan Booth – Labmate –
Researchers have described a preclinical strategy that uses targeted antibodies and epitope-edited stem cells to make blood stem cell transplantation safer and more precise for sickle cell disease, beta-thalassaemia, immune deficiencies and some blood cancers
A research group at the of the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, USA, has described a targeted strategy that could make blood stem cell transplantation and gene therapy safer by reducing reliance on the intensive chemotherapy or radiotherapy patients often need to complete prior to the start of cell and gene treatment.
